One of the most prevalent over-the-counter cold and cough medications is the chlorpheniramine maleate (CPM)–ibuprofen (IBF) combination. A reversed-phase high-performance liquid chromatography (RP-HPLC) method was effectively optimized and developed for the simultaneous detection of chlorpheniramine maleate and ibuprofen in a pharmaceutical formulation. The mobile phase for the RP-HPLC method was an isocratic combination of acetonitrile and 0.01 M acetate buffer at pH 3.8 (55:45; v/v) on an Eclipse Plus C18 reversed phase column. An ultraviolet (UV) detector with a wavelength of 225 nm was used to detect the analytes at a flow rate of 1.0 mL/min. CPM and IBF were satisfactorily eluted, with mean retention times of 2.09 and 6.27 min, respectively. The approach was shown to be linear (R2 > 0.9998 for CPM and 0.9992 for IBF), precise (% RSD 3.02% for CPM and 3.48% for IBF), accurate (% recoveries 97.7–98.9% for CPM and 101–104.5% for IBF), specific, easy to use, sensitive, quick, and robust. Limits of detection (LODs) were found to be 10 and 27 μg/mL for CPM and IBF, respectively. Without interference from excipients, the validated method could be utilized in regular quality control analysis of various dosage combinations of hard gelatin capsules containing CPM and IBF.
20 February 2023 in Journal of Pharmaceutical Innovation
Background: Abuse-deterrent formulations (ADFs) are dosage forms designed to prevent or discourage the misuse of prescription drugs, particularly opioids. They achieve this aim by either minimizing the benefit of tampering with the dosage form or making it challenging to change this dosage form. Therefore, one of the priorities for public health is to develop dosage forms that have abuse-deterrent formulations. The escalation in the prescription of opioids has led to a surge in their abuse or misuse, resulting in a high mortality rate. Objectives: This review article explores drug abuse methods among addicted individuals and lists the most frequently abused drug classes. Furthermore, this review concentrates on understanding the most prevalent technologies used to deter abuse of prescribed opioid drugs. Methods: The search included online published databases from PubMed, Google Scholar, Research Gate, Science Direct, Elsevier, and others. The objective was to collect as much information as possible from articles using the keywords “abuse deterrent formulations and abuse deterrent technology." Conclusions: Physical-chemical barriers and agonist-antagonist formulations are available as marketed drugs as well as aversive agents’ formulations. Each of these types can inhibit or reduce specific cases of opioid misuse. Although the success of these products mostly relies on robust formulation strategies, it also requires a thorough understanding of their benefits and broad adoption in the market.